

# Nilofer S Azad

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11152664/nilofer-s-azad-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25  
papers

13,271  
citations

21  
h-index

25  
g-index

25  
ext. papers

16,530  
ext. citations

10.9  
avg, IF

5.48  
L-index

#	Paper	IF	Citations
25	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 954-963	4.9	2
24	A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. <i>Clinical Epigenetics</i> , <b>2021</b> , 13, 25	7.7	3
23	Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4842-4851	12.9	33
22	Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). <i>Chinese Clinical Oncology</i> , <b>2020</b> , 9, 2	2.3	21
21	Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. <i>Lancet Oncology</i> , <b>2020</b> , 21, e135-e145	21.7	78
20	Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	10
19	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. <i>Cancer Medicine</i> , <b>2020</b> , 9, 1485-1494	4.8	25
18	Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 214-222	2.2	53
17	The DNA Damaging Revolution: PARP Inhibitors and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2019</b> , 39, 185-195	7.1	81
16	Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 886-895	12.5	76
15	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	172
14	Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease <b>2018</b> , 6, 35		114
13	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , <b>2017</b> , 357, 409-413	55.3	3274
12	Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. <i>Oncotarget</i> , <b>2017</b> , 8, 35326-35338	3.3	52
11	Epigenetic therapy for solid tumors: from bench science to clinical trials. <i>Epigenomics</i> , <b>2015</b> , 7, 215-35	4.4	46
10	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 2509-20	59.2	5560
9	A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 68-76	12.9	56

8	Mutational profiling of colorectal cancers with microsatellite instability. <i>Oncotarget</i> , <b>2015</b> , 6, 42334-44	3.3	54
7	Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. <i>Oncotarget</i> , <b>2014</b> , 5, 587-98	3.3	299
6	Detection of circulating tumor DNA in early- and late-stage human malignancies. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 224ra24	17.5	2741
5	. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7749	12.9	
4	Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1411-6	12.9	118
3	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3709-14	2.2	288
2	Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. <i>Cancer</i> , <b>2008</b> , 112, 1726-32	6.4	39
1	Keratoacanthomas associated with sorafenib therapy. <i>Journal of the American Academy of Dermatology</i> , <b>2007</b> , 56, 171-2	4.5	76